Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.62 |
| ▸ | P4HB | P07237 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.62 |
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233251 | 1.00 | CYP3A4 (0.62) | CYP3A4MAPTCYP2C9NFKB1CYP2C19 | |
| SCHEMBL25196348 | 0.85 | MAOB (0.66) | CYP3A4MAPTCYP2C9NFKB1CYP2C19 | |
| SCHEMBL25216445 | 0.85 | TNFRSF1A (0.57) | CYP3A4MAPTNFKB1P4HBTDP1 | |
| SCHEMBL25193684 | 0.84 | MAOB (0.61) | CYP3A4MAPTP4HBMEN1HPGD | |
| SCHEMBL25218131 | 0.81 | MAOB (0.61) | MAPTP4HBMEN1HPGDKMT2A | |
| SCHEMBL25214713 | 0.81 | MAPT (0.58) | MAPTNFKB1P4HBMEN1HPGD | |
| SCHEMBL31233147 | 0.81 | MAOB (0.61) | MAPTP4HBMEN1HPGDKMT2A | |
| SCHEMBL25197224 | 0.81 | MAPT (0.58) | MAPTNFKB1P4HBMEN1HPGD | |
| SCHEMBL25231544 | 0.81 | MAOB (0.61) | MAPTP4HBMEN1HPGDKMT2A | |
| SCHEMBL31233418 | 0.81 | MAOB (0.61) | MAPTP4HBMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021182896-A1 | INDUCED BROWN FAT DIFFERENTIATION COMPOSITION COMPRISING ISOLIQUIRITIGENIN DERIVATIVE | 가톨릭관동대학교산학협력단 | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CYP3A4 928/4885MAPT 3297/4885CYP2C9 124/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CYP3A4 1589/4885MAPT 3512/4885CYP2C9 1237/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CYP3A4 1589/4885MAPT 3512/4885CYP2C9 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.